FDA pharmacologic class
Substance P/Neurokinin-1 Receptor Antagonist
3 medicines are in FDA's class of substance p/neurokinin-1 receptor antagonists: aprepitant (Emend), fosaprepitant (Emend) and rolapitant (Varubi); 2 combination products also contain one. 2 of the 5 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is aprepitant 40 mg capsule at $46.42 per capsule (NADAC).
Which medicines are substance p/neurokinin-1 receptor antagonist?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Aprepitant | Emend, Aponvie, Cinvanti | 5 labelers | $46.42 per capsule 40 mg capsule | No | A presentation being discontinued | 3 |
| Fosaprepitant | Focinvez, Navitrux, Emend | 16 labelers | n/a | No | A presentation being discontinued | 3 |
| Fosnetupitant and palonosetron | Akynzeo | none listed | n/a | No | No current entry | 0 |
| Rolapitant | Varubi | none listed | n/a | No | No current entry | 0 |
| Netupitant and palonosetron | Akynzeo | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price